Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
Go back to Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease| (NASDAQ: ARVN) | Delayed: 7.64 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.64 | 52 Week High | $ | |||
| Open | $7.64 | 52 Week Low | $ | |||
| Day High | $7.64 | P/E | N/A | |||
| Day Low | $7.64 | EPS | $ | |||
| Volume | 981 | |||||



